QUEBEC CITY, April 29 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced it has received notification from the Nasdaq Stock Market ("Nasdaq") that it has regained compliance with Listing Rule 5450 (a) (1) relating to the maintenance of a minimum bid price.
Pursuant to this rule, the Company was required to evidence a closing bid price of at least $1.00 per share for a period of ten consecutive trading days. AEterna Zentaris completed this period on April 27, 2009.
AEterna Zentaris has confirmed that it currently meets all requirements for continued listing on the Nasdaq Global Market and continues to be listed on this exchange.
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.
CONTACT: Investor Relations: Ginette Vallieres, Investor Relations
Coordinator, (418) 652-8525 ext. 265, gvallieres@aezsinc.com; Media
Relations: Paul Burroughs, Director of Communications, (418) 652-8525 ext.
406, pburroughs@aezsinc.com